28958-90-9 Usage
Uses
Used in Pharmaceutical Industry:
(7S)-2-amino-4,5,6,7-tetrahydro-1H-1,3-diazepine-7-carboxylic acid is used as a building block for the development of new pharmaceutical compounds, particularly for neurological and psychiatric disorders. Its unique molecular structure and functional groups allow for the creation of drugs with specific targeting and therapeutic properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (7S)-2-amino-4,5,6,7-tetrahydro-1,3-diazepine-7-carboxylic acid serves as a valuable compound for studying the structure-activity relationships of potential drug candidates. Its cyclic structure and functional groups can be modified to explore various chemical and biological properties, contributing to the advancement of drug discovery and development.
Used in Drug Design and Synthesis:
(7S)-2-amino-4,5,6,7-tetrahydro-1H-1,3-diazepine-7-carboxylic acid is utilized as a key intermediate in the synthesis of complex drug molecules. Its incorporation into drug candidates can enhance their pharmacological properties, such as potency, selectivity, and bioavailability, making it a valuable asset in the design and synthesis of novel therapeutic agents.
Used in Drug Targeting:
Due to its unique structure and functional groups, (7S)-2-amino-4,5,6,7-tetrahydro-1H-1,3-diazepine-7-carboxylic acid can be employed in the development of targeted drug delivery systems. These systems can improve the specificity of drug action, reducing side effects and increasing the overall efficacy of treatment for neurological and psychiatric disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 28958-90-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,9,5 and 8 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 28958-90:
(7*2)+(6*8)+(5*9)+(4*5)+(3*8)+(2*9)+(1*0)=169
169 % 10 = 9
So 28958-90-9 is a valid CAS Registry Number.
